Dimerix Receives First Development Milestone Payment From Japan Partner

MT Newswires Live

06-30

Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.

DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.

The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.

Shares rose nearly 2% in morning trade Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2547031511"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547031511\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2547031511?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547031511","market":"us","top_or_hot":-1,"title":"Dimerix Receives First Development Milestone Payment From Japan Partner","media":"MT Newswires Live","content":"<html><body><p> Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.</p><p>DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.</p><p>The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.</p><p>Shares rose nearly 2% in morning trade Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Receives First Development Milestone Payment From Japan Partner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Receives First Development Milestone Payment From Japan Partner\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-30 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.</p><p>DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.</p><p>The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.</p><p>Shares rose nearly 2% in morning trade Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2547031511","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547031511","pubTimestamp":1751247381,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dimerix  received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.Shares rose nearly 2% in morning trade Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","DXB.AU":"DIMERIX LTD","BK7501":"新冠治疗股","BK7067":"生物科技"},"translate_title":"Dimerix收到日本合作伙伴的首笔开发里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB.AU":0.9},"content_text":"Dimerix (ASX:DXB) received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.Shares rose nearly 2% in morning trade Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}